NEW YORK — The Dow Jones Industrial Average rose 0.5 percent to 52,485 Tuesday, but the broader market has not confirmed a decisive upward move. Investors are growing cautious as several high-profile companies prepare to release quarterly results.
The Nasdaq Composite gained 1.0 percent to 25,374 and the S&P 500 climbed 0.7 percent to 7,490. Despite those daily advances, market participants have not pushed indices past critical resistance levels, suggesting weak conviction in the rally.
The hesitancy reflects rising risk of earnings disappointments. Major reports from Advanced Micro Devices, Western Digital's SanDisk unit and Eli Lilly are due next week.
SpaceX, a private company, offers no public financials, but analysts will scrutinize any company updates or media reports for data on Starlink subscriber growth and launch cadence. Strong Starlink performance in new markets would signal revenue expansion. Delays in Starship development or a slowdown in government contracts could weigh on sentiment across the private space sector.
AMD faces high expectations as a key player in the AI chip market. Investors will watch data center segment revenue and guidance for its MI300X accelerators. Any slowdown in AI chip demand or increased competition from Nvidia could pressure the stock. AMD's ability to hold gross margins above 50 percent in its high-performance computing division will be critical, and its gaming and client segments provide a read on PC market health.
Western Digital will offer a window into the memory and storage markets. Demand for NAND flash and hard disk drives has been volatile, driven by enterprise data center spending and consumer electronics sales. Analysts will focus on revenue trends across its Flash and HDD units, along with commentary on pricing power, inventory levels and cloud infrastructure spending.
Eli Lilly's results will center on its GLP-1 drugs—Zepbound for weight loss and Mounjaro for diabetes—which are the company's primary growth engine. Investors will track Zepbound's sales figures and market share gains against rivals. Pipeline updates in oncology and immunology will also factor into the long-term view.
